Updated guidance on preventing atherosclerotic cardiovascular disease in people with dyslipidemia includes changes reflecting ...

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Detailed price information for Adv Micro Devices (AMD-Q) from The Globe and Mail including charting and trades.

Rising incidences of CVDs have been linked to poor diet, lack of physical activity, tobacco use, excessive alcohol consumption, high blood pressure, and genetic predisposition. Repatha evolocumab ...

It reported stronger profit for the latest quarter than expected, thanks in part to growth for its Repatha medicine, which can lower bad cholesterol and reduce the risk of heart attack.

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

Repatha generated revenues of $606 million, up 45% year over year, driven by higher volume growth. Repatha volume growth was driven by broad reimbursement and removal of prior authorization ...